Drug intelligence / Profile preview

nonpegylated liposomal doxorubicin + paclitaxel

Development stage: Unknown
Lead developer: Sopherion Therapeutics
Modality: Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

This combination involves **nonpegylated liposomal doxorubicin**, a formulation designed to reduce the toxicity associated with conventional doxorubicin, and **paclitaxel**, a taxane that stabilizes microtubules, preventing cell division. The combination is used in the treatment of breast cancer, particularly in HER2-positive cases. Nonpegylated liposomal doxorubicin is encapsulated in liposomes to improve delivery and reduce side effects like cardiotoxicity and hand-foot syndrome, while paclitaxel acts by inhibiting cell division.

Targets

TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))DNA

Beyond the preview

Go deeper on nonpegylated liposomal doxorubicin + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nonpegylated liposomal doxorubicin + paclitaxel.

Explore the full profile